NCT00006091 2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Phase 2 Withdrawn
Clinical Trials
6 trialsNCT01835288 2018-05-21
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Stanford University
Phase 2 Withdrawn
NCT00504101 2016-12-15
Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma
University of Miami
Phase 1 Withdrawn
NCT00670150 2015-10-27
New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
University of Southern California
Phase 2 Withdrawn
NCT00075413 2015-10-02
Arsenic Trioxide in Treating Women With Locally Advanced or Metastatic Breast Cancer
The University of Texas Medical Branch, Galveston
Phase 2 Withdrawn
NCT00112879 2013-07-10
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Phase 2 Withdrawn